Valley Fever Meningitis: Diagnosis, Treatment, and Management of Coccidioidal CNS Infection
What are the symptoms of Valley Fever meningitis. How is coccidioidal meningitis diagnosed. What are the treatment options for Coccidioides infection of the central nervous system. What complications can arise from Valley Fever meningitis. Why is lifelong antifungal therapy recommended for coccidioidal meningitis.
Understanding Coccidioidal Meningitis: A Serious Complication of Valley Fever
Coccidioidal meningitis (CM) is a severe form of extrapulmonary dissemination that occurs when Coccidioides fungi spread to the central nervous system (CNS). This condition represents one of the most dangerous complications of Valley Fever, a fungal infection endemic to certain regions of the Americas. Understanding the pathophysiology, diagnosis, and management of CM is crucial for healthcare providers treating patients with suspected or confirmed coccidioidomycosis.
What is coccidioidal meningitis?
Coccidioidal meningitis is an infection of the membranes surrounding the brain and spinal cord caused by Coccidioides species fungi. It occurs when the fungal infection spreads from the lungs to the central nervous system, leading to inflammation and potentially life-threatening complications if left untreated.
Recognizing the Symptoms of Coccidioidal Meningitis
Identifying the symptoms of CM is crucial for early diagnosis and intervention. Patients with coccidioidal meningitis may present with a range of neurological symptoms that can be easily mistaken for other conditions.
What are the common symptoms of coccidioidal meningitis?
- Persistent headache
- Blurred vision
- Photophobia (sensitivity to light)
- Meningismus (neck stiffness)
- Cognitive decline
- Changes in hearing
- Focal neurologic deficits
It’s important to note that these symptoms can vary in severity and may develop gradually over time. Any patient with a history of coccidioidomycosis who experiences these neurological symptoms should be evaluated promptly for possible CM.
Diagnostic Approaches for Coccidioidal Meningitis
Accurate diagnosis of CM requires a combination of clinical assessment, laboratory tests, and imaging studies. The gold standard for diagnosis involves analysis of cerebrospinal fluid (CSF) obtained through lumbar puncture.
How is coccidioidal meningitis diagnosed?
The diagnosis of CM is based on the following criteria:
- Positive serologic testing (ID/CF) in CSF
- Culture of Coccidioides from CSF
- CSF analysis showing:
- Elevated white blood cell count with mixed or lymphocytic pleocytosis
- High protein levels (sometimes measurable in g/dL)
- Low glucose levels
- Imaging studies to evaluate complications associated with meningitis
It’s worth noting that a recent retrospective study found no evidence to support routine CSF analysis in patients without CNS symptoms, even if they belong to at-risk groups based on age, ethnicity, or CF titer.
Treatment Strategies for Coccidioidal Meningitis
The management of CM has evolved significantly over the years, with modern antifungal medications dramatically improving patient outcomes. However, treatment remains challenging due to the need for prolonged therapy and potential complications.
What is the primary treatment for coccidioidal meningitis?
The current standard of care for CM involves oral fluconazole therapy. Most clinicians initiate treatment with high doses of fluconazole, typically ranging from 800 to 1200 mg per day. This approach is based on clinical experience and uncontrolled trials that have shown favorable outcomes with fluconazole therapy.
Are there alternative treatments for coccidioidal meningitis?
Before the advent of azole antifungals, amphotericin B deoxycholate (AmB) was the only available treatment option. However, intravenous AmB was ineffective against CM, necessitating intrathecal (IT) administration. Due to the challenges and toxicities associated with IT AmB, it is rarely used as initial therapy today. In salvage situations, lipid formulations of AmB have been used successfully.
Complications and Long-term Management of Coccidioidal Meningitis
CM can lead to severe complications that require ongoing management and may significantly impact a patient’s quality of life.
What are the potential complications of coccidioidal meningitis?
- Hydrocephalus
- CNS vasculitis
- Cerebral ischemia and infarction
- Vasospasm
- Hemorrhage
- Basilar meningitis
- Spinal cord involvement
Hydrocephalus, in particular, often requires the placement of a ventricular shunt for decompression. These shunts can lead to additional complications, including secondary infections, obstruction due to persistent coccidioidomycosis, and abdominal pseudocysts. Patients may require multiple shunt revisions throughout their treatment course.
Monitoring Treatment Response and Long-term Prognosis
Assessing a patient’s response to CM therapy requires ongoing clinical evaluation and judgment. Favorable signs of improvement include:
- Return to premorbid functioning
- Decreasing complement fixation (CF) titers
- Excellent adherence to medical care and therapy
However, it’s important to note that some patients with chronic meningitis may experience refractory illness with poor recovery or exceptionally slow improvement.
How is treatment response monitored in coccidioidal meningitis?
Monitoring treatment response typically involves:
- Serial clinical evaluations
- Repeated CSF analysis to assess microbiologic and serologic improvement
- Tracking of CF titers
- Adherence counseling to ensure patients maintain their treatment regimen
It’s worth noting that while symptoms may resolve within 4-8 months of initiating fluconazole therapy, CSF abnormalities may persist, especially in the presence of a shunt.
The Importance of Lifelong Therapy in Coccidioidal Meningitis
One of the most critical aspects of CM management is the need for lifelong antifungal therapy. This recommendation is based on clinical experience and the high risk of relapse observed when treatment is discontinued.
Why is lifelong antifungal therapy recommended for coccidioidal meningitis?
The necessity for lifelong treatment stems from a small series of cases that demonstrated an extremely high relapse rate of 78% when therapy was discontinued. This finding underscores the persistent nature of Coccidioides infection in the CNS and the importance of maintaining ongoing antifungal suppression to prevent recurrence.
Challenges in Coccidioidal Meningitis Research and Future Directions
Despite advances in the understanding and treatment of CM, several challenges remain in the field. These challenges present opportunities for future research and improvements in patient care.
What are the current research priorities in coccidioidal meningitis?
- Developing more effective and less toxic antifungal agents
- Investigating combination therapies to improve treatment outcomes
- Exploring immunomodulatory approaches to enhance host defense against Coccidioides
- Improving diagnostic techniques for earlier detection of CNS involvement
- Studying the long-term outcomes of patients on lifelong antifungal therapy
Addressing these research priorities could lead to significant improvements in the management of CM and potentially reduce the need for lifelong therapy in some patients.
Are there any emerging treatments for coccidioidal meningitis?
While current treatment options for CM are limited, ongoing research is exploring new possibilities:
- Novel antifungal agents with improved CNS penetration
- Targeted immunotherapies to boost the immune response against Coccidioides
- Advanced drug delivery systems to enhance the efficacy of existing antifungals
- Personalized treatment approaches based on genetic factors and biomarkers
These emerging treatments hold promise for improving outcomes in patients with CM, but further clinical trials are needed to establish their safety and efficacy.
Patient Education and Support in Coccidioidal Meningitis Management
Given the chronic nature of CM and the need for lifelong therapy, patient education and support play crucial roles in ensuring optimal outcomes.
How can healthcare providers support patients with coccidioidal meningitis?
Healthcare providers can support patients with CM through several strategies:
- Comprehensive education about the disease and its management
- Regular follow-up appointments to monitor treatment progress and address concerns
- Psychological support to help patients cope with the chronic nature of the condition
- Assistance with medication adherence through reminders and support systems
- Coordination of care among different specialists involved in managing complications
- Providing resources for patient support groups and educational materials
By implementing these support measures, healthcare providers can help patients navigate the challenges of living with CM and maintain a good quality of life despite the ongoing treatment requirements.
The Role of Prevention in Reducing Coccidioidal Meningitis Cases
While treatment of CM is critical, prevention of coccidioidomycosis infection is equally important in reducing the incidence of this severe complication.
What preventive measures can be taken to reduce the risk of coccidioidal meningitis?
Preventive strategies for coccidioidomycosis and its complications include:
- Awareness campaigns in endemic areas to educate the public about Valley Fever
- Dust control measures in construction and agricultural settings
- Use of personal protective equipment in high-risk occupations
- Early diagnosis and treatment of primary coccidioidomycosis to prevent dissemination
- Close monitoring of at-risk patients for signs of CNS involvement
- Research into potential vaccines against Coccidioides infection
By implementing these preventive measures, it may be possible to reduce the overall burden of coccidioidomycosis and, consequently, the incidence of CM.
Conclusion
Coccidioidal meningitis remains a significant challenge in the management of Valley Fever. Its diagnosis requires a high index of suspicion, particularly in patients from endemic areas presenting with neurological symptoms. The current standard of care involves high-dose fluconazole therapy, often continued lifelong due to the high risk of relapse. Despite advances in treatment, CM can lead to severe complications and long-term morbidity.
Ongoing research into novel therapies, improved diagnostic techniques, and preventive strategies offers hope for better outcomes in the future. Healthcare providers play a crucial role not only in the medical management of CM but also in providing comprehensive support to patients navigating this chronic condition. As our understanding of coccidioidal meningitis continues to evolve, so too will our ability to effectively treat and potentially prevent this serious complication of Valley Fever.
Coccidioidal Meningitis | UC Davis Center for Valley Fever
Skip to main content
Center for Valley Fever
News | Careers | Giving | UC Davis Health
- UC Davis Health
- Center for Valley Fever
- About Valley Fever
The most deleterious extrapulmonary dissemination is the spread of Coccidioides spp. to the central nervous system (CNS) causing meningitis. A lumbar puncture with analysis of cerebrospinal fluid (CSF) should be done in any patient with suspected or previously diagnosed coccidioidomycosis presenting with a headache, blurry vision, photophobia, meningismus, decline in cognition, hearing changes, and focal neurologic deficit. As illustrated in a recent retrospective study there is no evidence to support routine CSF analysis in patients in at-risk groups (age, ethnicity, CF titer, etc. ) if they do not have CNS symptoms (1). The diagnosis of CM is based on a positive serologic testing (ID/CF) or culture of CSF. CSF analysis typically shows an elevated white blood cell count with a mixed or lymphocytic pleocytosis, a high level of protein (sometimes measurable in g/dL rather than mg/dL), and a low level of glucose. Imaging studies are helpful in evaluating complications associated with meningitis. Initial features of illness may be difficult to distinguish from other etiologies without detailed testing, notably tuberculosis and even autoimmune illnesses.
When left untreated, CM is uniformly fatal (2). In a historical series reported by Vincent et al, before the availability of antifungals, seventeen patients with CM were followed all of whom died within 31 months (2). This review also commented on the combined survival statistics described in five reports of 117 patients where 91% of patients with CM died within one year and all died within 2 years. Though the fatality has improved with the use of AmB and azoles, morbidity is still substantial due to complications from the disease, devices used for treatment management, and side effects of the medications as much higher recommended doses are necessary for prolonged period of time (3).
The most common life-threatening complications of meningitis include hydrocephalus, CNS vasculitis, cerebral ischemia, infarction, vasospasm and hemorrhage. Basilar meningitis and spinal cord involvement may also be encountered. In patients with hydrocephalus, a ventricular shunt is necessary for decompression. Such shunts, often placed distally into the abdominal cavity may develop secondary infections, obstruction due to persistent coccidioidomycosis, and/or abdominal pseudocysts (4). It is not uncommon for patients to require multiple shunt revisions. As illustrated in several case reports, repeated obstruction of the shunt and isolation of fungus should alert one to seek alternate antifungal therapy. Some clinicians have used steroids for vasculitis though this is considered anecdotal.
For treatment of CM, most clinicians prefer therapy with oral fluconazole (5). Although the dose studied in an uncontrolled clinical trial was 400 mg, it is common to begin therapy with 800 to 1200 mg per day of fluconazole (3, 6). Prior to the advent of azoles, amphotericin B deoxycholate (AmB) was the only drug of choice but was ineffective when given intravenously and required frequent administrations via the intrathecal (IT) route. Due to challenges of administration, toxicity associated with this route and lack of experience in utilizing this method, current practitioners seldom resort to recommending AmB as initial therapy although lipid formulations have been used in the salvage setting successfully (7). Though there are no trials comparing IT AmB and fluconazole, the response rate of IT AmB has ranged from 51%-100% in studies published before 1986 and with fluconazole the rate is near 79% (6, 8). With fluconazole symptoms resolve within 4-8 months though there is a delay in normalization of CSF abnormalities which may persist in the presence of a shunt. Based on clinical experience and due to an extremely high relapse of 78% noted in a small series when therapy is discontinued, lifelong treatment with azoles is recommended (9).
Assessing a patient’s response to therapy is primarily a matter of serial evaluation and clinical judgment. Favorable signs include return to premorbid functioning, decreasing CF titers, and excellent adherence to medical care and therapy. Some patients with chronic meningitis have refractory illness with poor recovery or exceptionally slow improvement. A combination of serology and repeated CSF evaluation may be necessary to assess microbiologic and serologic improvement. Adherence counseling, assessment of drug-drug interactions, therapeutic drug monitoring, and consideration of alternative antifungal therapy may be necessary. For CM patients who are failing treatment and/or have refractory coccidioidal disease, salvage regimens may be necessary. Both voriconazole and posaconazole have been used in this situation, with a growing body of case series and clinical experience to support their use.
REFERENCES
- Thompson G, 3rd, Wang S, Bercovitch R, et al. Routine CSF Analysis in Coccidioidomycosis Is Not Required. PloS one 2013; 8(5): e64249.
- Vincent T, Galgiani JN, Huppert M, Salkin D. The natural history of coccidioidal meningitis: VA-Armed Forces cooperative studies, 1955-1958. Clin Infect Dis 1993; 16(2): 247-54.
- Johnson RH, Einstein HE. Coccidioidal meningitis. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2006; 42(1): 103-7.
- Hibbett DS, Binder M, Bischoff JF, et al. A higher-level phylogenetic classification of the Fungi. Mycol Res 2007; 111(Pt 5): 509-47.
- Galgiani JN, Ampel NM, Blair JE, et al. Coccidioidomycosis. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2005; 41(9): 1217-23.
- Galgiani JN, Catanzaro A, Cloud GA, et al. Fluconazole therapy for coccidioidal meningitis. The NIAID-Mycoses Study Group. Annals of internal medicine 1993; 119(1): 28-35.
- Mathisen G, Shelub A, Truong J, Wigen C. Coccidioidal meningitis: clinical presentation and management in the fluconazole era. Medicine 2010; 89(5): 251-84.
- Bouza E, Dreyer JS, Hewitt WL, Meyer RD. Coccidioidal meningitis. An analysis of thirty-one cases and review of the literature. Medicine 1981; 60(3): 139-72.
- Dewsnup DH, Galgiani JN, Graybill JR, et al. Is it ever safe to stop azole therapy for Coccidioides immitis meningitis? Annals of internal medicine 1996; 124(3): 305-10.
Valley fever – Symptoms & causes
Overview
Valley fever is a fungal infection caused by coccidioides (kok-sid-e-OY-deze) organisms. It can cause signs and symptoms such as a fever, cough and tiredness.
Two coccidioides fungi species cause valley fever. These fungi are commonly found in soil in specific regions. The fungi’s spores can be stirred into the air by anything that disrupts the soil, such as farming, construction and wind.
People can then breathe the fungi into their lungs. The fungi can cause valley fever, also known as acute coccidioidomycosis (kok-sid-e-oy-doh-my-KOH-sis). Mild cases of valley fever usually resolve on their own. In more-severe cases, doctors treat the infection with antifungal medications.
Products & Services
Symptoms
Valley fever is the initial form of coccidioidomycosis infection. This initial, acute illness can develop into a more serious disease, including chronic and disseminated coccidioidomycosis.
Acute coccidioidomycosis (valley fever)
The initial, or acute, form of coccidioidomycosis is often mild, with few or no symptoms. Signs and symptoms occur one to three weeks after exposure. They tend to be similar to flu symptoms. Symptoms can range from minor to severe, including:
- Fever
- Cough
- Tiredness
- Shortness of breath
- Headache
- Chills
- Night sweats
- Joint aches and muscle soreness
- Red, spotty rash, mainly on lower legs but sometimes on the chest, arms and back
If you don’t become ill or have symptoms from valley fever, you may only find out you’ve been infected later. You may find out when you have a positive skin or blood test or when small areas of residual infection in the lungs (nodules) show up on a routine chest X-ray. The nodules typically don’t cause problems, but they can look like cancer on X-rays.
If you develop symptoms, especially severe ones, the course of the disease is highly variable. It can take months to fully recover. Fatigue and joint aches can last even longer. The disease’s severity depends on several factors, including your overall health and the number of fungus spores you inhale.
Chronic coccidioidomycosis
If the initial coccidioidomycosis infection doesn’t completely resolve, it may progress to a chronic form of pneumonia. This complication is most common in people with weakened immune systems.
Signs and symptoms include:
- Low-grade fever
- Weight loss
- Cough
- Chest pain
- Blood-tinged sputum (matter discharged during coughing)
- Nodules in the lungs
Disseminated coccidioidomycosis
The most serious form of the disease, disseminated coccidioidomycosis, is uncommon. It occurs when the infection spreads (disseminates) beyond the lungs to other parts of the body. Most often these parts include the skin, bones, liver, brain, heart, and the membranes that protect the brain and spinal cord (meninges).
Signs and symptoms of disseminated disease depend on the body parts affected and may include:
- Nodules, ulcers and skin lesions that are more serious than the rash that sometimes occurs with initial infection
- Painful lesions in the skull, spine or other bones
- Painful, swollen joints, especially in the knees or ankles
- Meningitis — an infection of the membranes and fluid surrounding the brain and spinal cord
When to see a doctor
Seek medical care if you are over 60, have a weakened immune system, are pregnant, or are of Filipino or African heritage, and you develop the signs and symptoms of valley fever, especially if you:
- Live in or have recently traveled to an area where this disease is common
- Have symptoms that aren’t improving
Be sure to tell your doctor if you’ve traveled to a place where valley fever is common and you have symptoms.
Causes
Valley fever is caused by a person inhaling spores of certain fungi. The fungi that cause valley fever — Coccidioides immitis or Coccidioides posadasii — live in the soil in parts of Arizona, Nevada, Utah, New Mexico, California, Texas and Washington. It’s named after the San Joaquin Valley in California. The fungi can also often be found in northern Mexico and Central and South America.
Like many other fungi, coccidioides species have a complex life cycle. In the soil, they grow as a mold with long filaments that break off into airborne spores when the soil is disturbed. A person can then inhale the spores.
The spores are extremely small and can be carried far by the wind. Once inside the lungs, the spores reproduce, continuing the disease cycle.
Risk factors
Risk factors for valley fever include:
Environmental exposure. Anyone who inhales the spores that cause valley fever is at risk of infection. People who live in areas where the fungi are common — especially those who spend a lot of time outdoors — have a greater risk.
Also, people who have jobs that expose them to dust are most at risk — construction, road and agricultural workers, ranchers, archaeologists, and military personnel on field exercises.
- Race. For reasons that aren’t well understood, people of Filipino and African heritage are more susceptible to developing serious fungal infections.
- Pregnancy. Pregnant women are vulnerable to more-serious infections when they get the infection during the third trimester. New mothers are vulnerable right after their babies are born.
- Weakened immune system. Anyone with a weakened immune system is at increased risk of serious complications. This includes people living with acquired immunodeficiency syndrome (AIDS) or those being treated with steroids, chemotherapy and anti-rejection drugs after transplant surgery. People with certain autoimmune diseases, such as rheumatoid arthritis or Crohn’s disease, who are being treated with anti-tumor necrosis factor (TNF) drugs also have an increased risk of infection.
- Diabetes. People with diabetes may have a higher risk of severe lung infections.
- Age. Older adults are more likely to develop valley fever. This may be because their immune systems are less robust or because they have other medical conditions that affect their overall health.
Complications
Some people, especially pregnant women, people with weakened immune systems — such as those living with human immunodeficiency virus (HIV)/AIDS — and those of Filipino or African heritage are at risk of developing a more severe form of coccidioidomycosis.
Complications of coccidioidomycosis may include:
- Severe pneumonia. Most people recover from coccidioidomycosis-related pneumonia without complications. Others, such as people of Filipino and African heritage, and those with weakened immune systems, may become seriously ill.
- Ruptured lung nodules. A small percentage of people develop thin-walled nodules (cavities) in their lungs. Many of these eventually disappear without causing any problems, but some may rupture, causing chest pain and difficulty breathing. A ruptured lung nodule might require the placement of a tube into the space around the lungs to remove the air or surgery to repair the damage.
- Disseminated disease. This is the most serious complication of coccidioidomycosis but it’s uncommon. If the fungus spreads (disseminates) throughout the body, it can cause problems including skin ulcers, abscesses, bone lesions, severe joint pain, heart inflammation, urinary tract problems and meningitis — a potentially fatal infection of the membranes and fluid covering the brain and spinal cord.
Prevention
There is no vaccine to prevent valley fever.
If you live in or visit areas where valley fever is common, take common-sense precautions, especially during the dry season following a rainy season when the chance of infection is highest.
Consider these tips:
- Wear a mask.
- Avoid very dusty areas, such as construction sites.
- Stay inside during dust storms.
- Wet the soil before digging in it, or avoiding soil if you’re at higher risk of infection.
- Keep doors and windows tightly closed.
- Clean skin injuries with soap and water.
US drought resurrects fungus that causes fever and meningitis
Society
2867
Share
Photo: Global Look Press
Fires, floods and the record sting of 2022 certainly pose a great danger to human health. But dry weather in the United States in California has brought to life a disease-causing fungus that spreads by airborne droplets.
It’s called Coccidioides, and it causes Valley Fever. Its symptoms are crushing headaches and sinus infections. Worst of all, it can turn into meningitis.
Former financial planner and father of two, Rob Purry, first contracted a fever and then contracted meningitis. He complained that the illness had taken away all his health and all the money the family had.
Coccidioides requires a dry and hot climate to survive. Therefore, the disease, originally characteristic of the hot plains of California, is becoming more common. This was announced by infectious disease expert Dr. Royce Johnson.
Most of the western US is already in drought, added Morgan Gorris, an Earth system researcher at Los Alamos National Laboratory.
“The western half of the US is still expected to be fairly dry and Valley Fever is expected to spread,” he predicted.
It is important to note that soil, if left undisturbed, will not necessarily lead to inhalation of the disease. But any disturbance to the layer, whether it be a full-scale archaeological site or a burrowing animal, will release the fungus from the soil. Pathogenic spores can travel up to 75 miles (120 km).
Scientists recently warned that the next global pandemic could be fungal. Therefore, the growing spread of Coccidioides is of particular concern.
See also: “The number of cases of monkeypox infection in the world has exceeded 50 thousand”
Subscribe
Authors:
- org/Person”>
Anastasia Kukova
US
What else to read
What to read:More materials
In the regions
A tourist spoke about a traffic jam in front of the Crimean bridge: even children are being searched
34568
Crimea
photo: MK in Crimea
British visionaries: APU will enter the Crimea in a month
11337
Crimea
crimea. mk.ru
photo: MK in CrimeaCrimean Maldives: how the holiday season goes on the coolest beaches
Photo
10865
Crimea
Valeria Rudnik, photo by the author
July 7 is the day of Ivan Kupala, what is possible and what is strictly forbidden to do on a big holiday
Photo
9081
Pskov
What caused the worst railway accident in Karelia
Photo
8881
Karelia
Alexander Trubin
In Novosibirsk, the girl abandoned the child after the betrayal of her husband
4285
Novosibirsk
Daria Melekhova
In the regions:More materials
A rare type of meningitis for which there is no vaccine.
All About Fungal Meningitis
Fungal meningitis is an inflammation and infection of the membranes surrounding the brain and spinal cord.
There are different types of meningitis, including viral, bacterial and fungal. Of these, the latter, for example, is the rarest in the United States.
Fungal meningitis occurs when a fungus that has invaded another area of the body travels to the brain or spinal cord. Various types of fungi can cause fungal meningitis.
Types of fungal meningitis
Fungal meningitis is divided into types according to the type of fungus causing the infection. There are five types of fungal meningitis.
1. Cryptococcus Neoformans
Cryptococcus Neoformans is a type of fungus found throughout the world:
- in soil,
- bird droppings,
- rotting wood.
People can inhale the fungus after being in close contact with soil or other materials that contain it, but most people who are exposed to Cryptococcus neoformans do not get sick. However, it is the most common form of fungal meningitis, accounting for more than 70% of cases of fungal meningitis.
People with weakened immune systems are more likely to have a Cryptococcus neoformans infection, which can present as a lung infection or meningitis, depending on where in the body the infection occurs.
Cryptococcus neoformans infections are particularly common in people with advanced HIV/AIDS.
2. Coccidioides
Coccidioides is a fungus found in the soil of the southwestern United States, Washington State, Mexico, South America and Central America.
Coccidioidosis causes a condition called valley fever, or coccidioidomycosis. Valley fever can affect anyone and can take months to resolve. People with weakened immune systems are more likely to have severe cases, which can include meningitis.
Coccidioides is responsible for approximately 16% of cases of fungal meningitis.
3. Candida
Candida, better known as yeast, is a fungus that occurs naturally in the body but can cause an infection if it grows too fast or gets into an area of the body it shouldn’t – for example, into the meninges.
Some yeast infections, such as vaginal yeast infection or thrush, are localized to one area of the body, but forms of yeast infections or candidiasis can be invasive. Invasive candidiasis can enter the circulatory system and cause symptoms throughout the body.
About 8% of cases of fungal meningitis are associated with candidiasis.
4. Histoplasma
Histoplasma is a fungus found in bird and bat droppings, especially in the Ohio and Mississippi river valleys, although the fungus can be found far beyond this area.
Histoplasm causes an infection called histoplasmosis, which may include meningitis. Anyone can develop histoplasmosis, and in most cases the condition will go away on its own. However, people with suppressed immune systems are more likely to experience severe cases, including meningitis.
About 6% of cases of fungal meningitis are caused by histoplasma.
5. Blastomyces
Blastomyces is a fungus found in decaying leaves and wood, and in moist soil, especially in the Mississippi River Valley, Ohio River Valley, and Great Lakes regions of the United States.
Blastomycetes can cause an infection called blastomycosis. In most cases, there are no symptoms. However, this type of fungal meningitis is rare.
Symptoms of fungal meningitis
The symptoms of fungal meningitis are the same as the general symptoms of meningitis. These include fever, headache, and neck stiffness, especially when they occur at all. However, the temperature can be below 37.7°C, making it difficult to detect.
Other common symptoms of meningitis include:
- Pain
- Fatigue, drowsiness and trouble waking up
- Lack of appetite
- Nausea and vomiting
- Irritability and mood changes
Causes of fungal meningitis
Fungal meningitis occurs when a person is exposed to a fungus (usually by inhaling it), which then causes an infection in the body. Living in areas exposed to harmful fungi can increase your risk of contracting fungal meningitis. However, people with underlying medical conditions or weakened immune systems are most at risk.
Risk factors
People with weakened immune systems are more likely to get fungal meningitis, as mentioned above. A weakened immune system may be due to:
- Health conditions such as HIV or cancer
- Medicines such as steroids, immunosuppressants and TNF inhibitors
- Various health conditions
- Premature babies are also at higher risk of fungal infections, especially Candida.
Diagnosis
If meningitis is suspected, the doctor will order a blood test and a lumbar puncture, in which cerebrospinal fluid is removed from the spine. Using these samples, the doctor will be able to determine the cause of the infection. This is especially important in the case of fungal meningitis, as the type of fungus you are exposed to will determine the course of treatment.
Treatment of fungal meningitis
Antifungal drugs will be used to treat fungal infections of the nervous system, including fungal meningitis.